John Rossi

John Rossi

Company: CERo Therapeutics

Job title: Senior Vice President, Translational Medicines & Research


Development & Functional Characterisation of Chimeric Engulfment Receptor (CER) T-Cells for the Treatment of Hematologic & Solid Malignancies 8:15 am

New drug targets and next generation engineered T-cell products are needed to overcome current limitations of scFv- based CARs Novel CER-T cell products leveraging naturally occurring phagocytic receptors represent a new class of cell therapy products targeting tumour stress ligands Engulfment and enhanced APC-like function of CER-based products are hypothesised to overcome heterogeneous disease through…Read more

day: Day Two

Panel Discussion: Changing the Face of Cell Therapies with In Vivo Gene Engineering 3:00 pm

Exploring the potential to develop a universal cell therapy without ex vivo isolation/expansion of T-cells How can we improve safety, dosing and efficacy by using mRNA to create CAR-T cells in vivo? Discussing how to control the pharmacokinetic properties of the cell productRead more

day: Day 1 – Track A – Afternoon

Industry Leaders’ Fireside Chat – Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches 9:00 am

An executive panel discussion from the industry leaders of the field to set the scene on next generation CAR-TCR therapies. Ask your questions live to understand the expert’s thoughts on key topics including: Successes and hurdles to date: T-cell therapy translation to solid tumours, non-oncologic disorders and off-the-shelf (ex vivo and in vivo) T-cell engineering…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.